KyrgyzstanTuberculosis profile
Population  2014 5.8 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.65 (0.63–0.67) 11 (11–12)
Mortality (HIV+TB only) 0.055 (0.042–0.07) 0.94 (0.71–1.2)
Prevalence  (includes HIV+TB) 11 (5.4–20) 196 (93–336)
Incidence  (includes HIV+TB) 8.3 (7.3–9.3) 142 (126–160)
Incidence (HIV+TB only) 0.18 (0.16–0.2) 3.1 (2.7–3.5)
         
Case detection, all forms (%) 77 (68–87)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 26 (23–31) 55 (52–58)
MDR-TB cases among notified pulmonary
TB cases
1 100 (960–1 300) 850 (800–900)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 1 849   510
Pulmonary, clinically diagnosed 2 407    
Extrapulmonary 1 624    
       
Total new and relapse 6 390    
Previously treated, excluding relapses 1 033    
Total cases notified 7 423    
Among 5 880 new cases:
438 (7%) cases aged under 15 years; male:female ratio: 1.2
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB      
Laboratory-confirmed RR-/MDR-TB cases     1 267
Patients started on MDR-TB treatment ***     1 157
TB/HIV 2014 Number (%)
TB patients with known HIV status 7 052 (95)
HIV-positive TB patients 221 (3)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 118 (53)
HIV-positive TB patients on antiretroviral therapy (ART) 112 (51)
HIV-positive people screened for TB 2 147  
HIV-positive people provided with IPT 95  
Treatment success rate and cohort size (%) Cohort
New cases registered in 2013 (85) 5 658
Previously treated cases registered in 2013 (76) 1 130
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (63) 775
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 2.2
Culture (per 5 million population) 6.0
Drug susceptibility testing (per 5 million population) 1.7
Sites performing Xpert MTB/RIF 8
Is second-line drug susceptibility testing available? Yes, in and outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) 29
% Funded domestically 37%
% Funded internationally 63%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-09-27 Data: www.who.int/tb/data